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ABSTRACT
Malaria, the disease caused by Plasmodium sp., claims the lives of over 1 million people
every year, with Plasmodium falciparum causing the highest morbidity. Rapidly acquiring drug
resistance is threatening to exhaust our antimalarial drug arsenal and already requires the
utilization of combination drug therapy in most cases. The global need for novel antimalarial
chemical scaffolds has never been greater.
Screening of natural product libraries is known to have higher hit rates than synthetic
chemical libraries. This elevated hit rate is somewhat attributed to the greater biodiversity
available in natural products. Marine life is the most biodiverse system on the planet, containing
34 of the 36 known phyla of life, and is expected to be a rich source of novel chemotypes. In
collaboration with the Harbor Branch Oceanographic Institute in Ft. Pierce we have screened a
library of over 2,800 marine macroorganism peak fractions against Plasmodium falciparum
using the SYBR green I fluorescence-based assay. In this screening process we have identified
six compounds from five novel chemical scaffolds all of which have low micromolar to
submicromolar IC50 values and excellent selectivity indices. Additionally, one of these chemical
scaffolds, the bis(indolyl)imidazole, was selected for further in vitro pharmacological and
structure-activity relationship (SAR) profiling, key steps in the challenging process of identifying
a new antimalarial drug lead compound.
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CHAPTER ONE: INTRODUCTION
Malaria Background
Malaria, a term from the Latin words ‘mal’ ‘aria’ meaning ‘bad air’, is caused by the
parasite genus Plasmodium of the apicomplexan family. Once infected the most common
symptoms include fever, headache, malaise, myalgias, arthralgia, low back pain, nausea,
vomiting, diarrhea and cough [1]. The most prevalent human parasites are Plasmodium
falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malaria, and Plasmodium
knowlesi, with Plasmodium falciparum causing the highest global mortality [2]. Despite the fact
that Malaria has been a major cause of mortality and morbidity for thousands of years [3], recent
estimates conclude that around 3.3 billion people are still at risk of contracting malaria, and over
1,000,000 people die annually from the disease [2]. Over 85% of the mortality occurs in
children under 5 years old.
Plasmodium falciparum Life Cycle
The Plasmodium falciparum life cycle involves two separate hosts, the female Anopheles
mosquito and the human. The parasite enters the mosquito during a blood meal as exflagellated
motile microgametes and macrogametes [4]. These quickly form male and female gametocytes
which undergo gametogenesis to form ookinetes. The ookinetes then migrate to the mid-gut
epithelium basal lamina [5], where the ookinetes develop into oocytes and mature into
sporozoites that rupture through the basal lamina and migrate to the mosquito salivary gland [6].
Upon the mosquito’s next blood meal, sporozoites travel from the mosquito salivary gland and
into the human blood stream. Within 30 seconds to two minutes the sporozoites must travel
along the human blood stream and terminally lodge within hepatocyte cells where they will
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replicate to over 10,000 merozoites in a process called schizogony [7, 8]. Eventually, a
merosome, full of hundreds of merozoites, will bud and release the merozoites inside the blood
stream, each of which will infect a red blood cell [9]. Over the next 48 hours the intraerythrocytic merozoite will develop into a ring, then a trophozoite, followed by schizont. Within
the schizont stage the parasite undergoes many consecutive cycles of replication forming a 10-20
nucleated merozoites in what is called a segmenter stage. After entering segmenter stage the
parasites will egress from the red blood cell as many new merozoites, which struggle to find and
invade nearby red blood cells and begin the intra-erythrocytic process again. Upon release of the
merozoites from the red blood cell, tumor necrosis factor and other cytokines are also released
which explain the cyclical symptomology [9].
This asexual life cycle is broken approximately 1% of the time when a ring will form a
microgametes or a macrogametes [9]. These sexual stages can be brought into the mosquito
during a blood meal and will develop as mentioned above. The complete Plasmodium spp. life
cycle is depicted in figure 1.
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Figure 1 Plasmodium spp. Life Cycle [8]
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Current Treatment and Prevention Strategies
Per the World Health Organization (WHO) “Malaria is an entirely preventable and treatable
disease, provided that currently recommended interventions are properly implemented” [2]
Prevention
“The goals of malaria vector control are two-fold:
1) To protect individual people against infective malaria mosquito bites
2) To reduce the intensity of local malaria transmission at community level by reducing
the longevity, density and human-vector contact of the local vector mosquito
population” [2]
Insecticide Treated Bed NetsThe best preventative measure for malaria is utilizing insecticide treated bed nets (ITN’s).
These nets, originally tested in the 1990’s, showed a remarkable reduction in child mortality of
over 20% [10]! As early as 1898, the recognition that mosquito nets could reduce the parasite
load was being taught by Sir Ronald Ross [11]. The practice of saturating the bed nets in
pyrethroids shows similar decreases in child mortality and also shows some proximity protection
as well [12]. These long-lasting insecticide treated nets (LLIN) significantly decreased the
parasite load and the WHO recommended ceasing distributing a set number per household and
start distributing these nets universally as the protection is far greater under a net than it is by
proximity only [13]. Also, historically 96% of those who have a bed net will use it, suggesting
that this could be a great preventative measure [2].
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Indoor Residual SprayingA second line of defense is indoor residual spraying (IRS) of insecticides, preferably
long-lasting insecticides. This method requires multiple rounds of spraying each year and can be
somewhat costly, especially for very-low income countries [14]. Remarkably, 2010 showed an
increase in IRS usage with over 70% of countries using long-lasting pyrethroids. Although
many countries in Africa reported decreased usage of IRS, the western world (specifically China)
more than compensated to bring the increased total above what was done previously. The
dominating use of pyrethroids for both ITN’s and in IRS promotes concern for possible vector
resistance [2]. IRS can be from any of the other three insecticide classes: organochlorine (DDT),
organophosphate, or carbamate; whereas pyrethroids are the only ITN approved chemical class
at this time. Understandably, cost could be an issue, DDT is roughly the same price as the
relatively inexpensive pyrethroids, but organophosphates and carbamates can be as much as 4
times the price of pyrethroids [2]. Overall, of the reporting countries, 11% of at risk populations
are currently protected by IRS which, although increasing each year, still needs great
improvement, and it is clear that for a global increase in IRS use and availability, funding will
need to be increased.

VaccinationA third preventative option, an ideal one, could include vaccination against malaria.
Since 1910 development of a malaria vaccine has escaped the reach of the scientific community,
although many great strides have been taken. Most recently GlaxoSmithKline developed the
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RTS,S vaccine which combines circumsporozoite protein antibodies with a hepatitis B vector
and the AS01 immune response boosting adjuvant. This vaccine, also known as Mosquirix, is
currently undergoing phase III clinical trials. Preliminary findings suggest a decrease in
mortality by 50% in infants and children. These findings however, are yet to be verified [15]. If
successful, this could be the first malaria vaccine, although improvement is still needed to
increase efficacy beyond 50%.
Garcia-Basterio et al.[15] recommend that in order for a vaccine to be effective in
preventing malaria it is desirable that it has the following qualities:
-“Be effective preventing clinical disease, severe malaria and transmission in the
community
-Be completely safe for young infants and risk populations (pregnant women, people with
immune deficiencies or other co-morbidities), with a similar safety profile as other EPI
vaccines
-Provide protection against the 5 species of malaria plasmodia
-Provide long-lasting immunity
-Be administrable in the first months of life
-Single oral - dose regime compatible with vaccines of the expanded program on
immunization (EPI)
-Easily manufactured, deployed, stored and handled
-Affordable for governments of low income countries
-Stable at room temperature
-Available for travelers of non-endemic areas”
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Treatment
Currently there are over seven chemical classes used in the treatment of Plasmodium spp.
infections including: antifolates, endoperoxides, 4- and 8- aminoquinolines, sulfonamides, amino
alcohols, and antibiotics. Of these, the most common currently used chemical classes
(aminoquinolines, endoperoxides, and antifolates- including sulfonamides) will be discussed in
more detail.
It is important to note that the WHO recommends any treatment of malaria should
include combination therapy. As each chemical class has a different mode of action it is
believed that the growing trend of drug resistant parasites can be curtailed if combinations of
chemicals which inhibit different targets, as well as different stages of life cycle development are
used in conjunction. A brief structural representation of the different antimalarial drug classes
can be found in figure 2.
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Figure 2 Current Antimalarial Treatment Classes [16]
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4- and 8- Aminoquinolines

Figure 3- 4- and 8- Aminoquinolines

For almost 400 years aminoquinolines, like those in figure 3, have been used to treat
malaria. Isolated from Cinchona tree bark in the Andes mountain range, quinine use was taught
by the native South and Central American people to Spanish Jesuits in the early 1600’s [17].
Because of the limited cultivation and expense of quinine, it became apparent that direct
chemical synthesis was needed. Quinine derivatives were successfully synthesized as early as
the 1920’s and one particular derivative of note, Resochin, was synthesized in 1934 by Hans
Andersag. Unfortunately, Resochin was determined to be slightly more toxic than the previous
quinine derivative in use: Plasmochin, and the clinical study of Resochin ended prematurely
[18]. Nearly a decade later, under the US Board for the Coordination of Malarial Studies,
Resochin was rediscovered as the substance SN-7619, and was named Chloroquine though it was
structurally the identical of Resochin [18].
By the 1960’s, Chloroquine became one of the most widely sold of all medications and
its ability to serve as both a prophylactic and a preventative treatment only increased its
antimalarial value [7]. Chloroquine destroys the parasite by entering into the parasite digestive
vacuole and binding hematin (a toxic by-product of hemoglobin digestion by the parasite.).
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Normally, the hematin is polymerized into an inert hemozoin crystal. This detoxification is
disrupted by chloroquine and the build-up of toxic hematin destroys the parasite [19].
In 1955 the WHO began the Malaria Eradication Program utilizing chloroquine as the
sole treatment for infected humans, and the insecticide DDT to tackle the vector control [8].
Using these resources, the WHO successfully eradicated malaria from 24 countries by 1982.
Unfortunately, the nations where malaria was not eradicated soon were dominated by a rapid
wave of chloroquine resistant Plasmodium falciparum [20].
These resistant strains of P. falciparum were shown to have mutations in key transport
proteins which allowed the parasite to decrease chloroquine concentrations in the digestive
vacuole. This transport protein is called Plasmodium falciparum chloroquine resistant
transporter protein (pfcrt). Because of the decreased efficacy of chloroquine, many nations
discontinued its use and switched to antifolate combination therapy. Interestingly, after 8 years
of discontinued chloroquine use to treat malaria in Malawi, a test group of 210 patients treated
with chloroquine showed that chloroquine sensitivity was restored and that the use of
chloroquine was much more effective at reducing host parasitemia than the antifolate
combination therapy [21]. Similar studies in other nations also showed increased chloroquine
efficacy after discontinued use for some period of time. This lends credibility to the idea that if a
chemical treatment is shown to have resistance, it must be temporarily discontinued for some
time and then it may be brought back into use. The principle concept behind this is the belief
that the mechanism of resistance will be lost from the parasite over time. Jensen et al. describe
this practice as “drug cycling”. How effective this method will be over time, and whether or not
this method can be applied to other antimalarial drugs remains to be seen [7].
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Antifolates and Sulfonamides
Because of a rise in chloroquine resistant parasites, another chemical class of
antimalarials needed to be developed. This new chemical class was antifolates. Antifolates
inhibit the production of tetrahydrofolate, a necessary step in DNA, RNA, and protein
metabolism. Two signature targets of antifolates in Plasmodium spp. include inhibition of
dihydropteroate synthase (DHPS) by sulfonamides and inhibition of dihydrofolate reducatase
(DHFR) by pyrimethamine or cycloguanil. (Figure 4).
DHPS catalyzes the production of 7,8 dihydropteroate from 6-hydroxymethyl-7,8dihydropterin pyrophosphate and p-Aminobenzoic acid (pABA)[22]. It is clear that
sulfonamides, like sulfadoxine, bind to DHPS and, due to structural similarities, inhibit pABA
from interacting [23]. This is antagonistically reversible inhibition, as increasing pABA
concentrations in the media has been shown to decreases sulfadoxine activity [24].
In addition to sulfonamide mediated DHPS inhibition, another class of antifolates,
pyrimethamine, cycloguanil, etc., inhibit dihydrofolate reductase (DHFR). These chemicals
have a strong structural resemblance to dihydrofolic acid (the natural substrate of DHFR) and are
able to bind to DHFR and inhibit tetrahydrofolate production [25]. One of the major reasons that
antifolates, like pyrimethamine, are so advantageous in the treatment of malaria is the fact that
protozoan DHFR has a much greater affinity for these inhibitors than human DHFR [26].
Unfortunately, within a short number of years of acceptance as an antimalarial treatment,
cases of antifolate drug resistant Plasmodium strains surfaced [27]. Most methods of resistance
include DHFR or DHPS gene point mutations [28, 29]. which significantly decrease the binding
affinity for the drug(s). These mutations could have arisen from the many years of sulfadoxine
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and pyrimethamine combination therapy that replaced chloroquine treatment throughout Africa.
Although inexpensive and valued for its single dose treatment, the slow excretion of these drugs
from the body could also have facilitated resistance development [3].

Figure 4- Folate Biosynthesis (http://priweb.cc.huji.ac.il/malaria//maps/folatebiopath.html)

Endoperoxides
Endoperoxides are derived from the parent compound artemisinin (Figure 5).
Artemisinin, or qinghaosu, is a natural compound from the plant Artemisia annua. Lacking the
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typical nitrogen-substituted rings, the sesquiterpene lactone artemisinin has a peroxide bridge
making it very unique among antimalarial drug classes [30]. Although the mechanism of action
is still unknown, it is believed that within the digestive vacuole the peroxide reacts with the heme
to produce free radicals [31] which can lead to the disruption of lipid membranes [32] and the
alkylation of specific intracellular targets (heme or other proteins like metalloporphyrins [33]).
One of the great benefits of Artemisinin is a rapid treatment response backed with a short
half-life [34]. Most cases of infection can be eliminated completely after the first 48 hours of
artemisinin treatment [35]. This swift action also provides successful treatment of potentially
fatal cerebral malaria [36]. Unfortunately, the speed of action, like a two edged sword, has been
cited in studies as a potential for developing drug resistance, as many patients after the first dose
would begin to feel better and would stop treatment before total parasite elimination was
completed [37, 38]. In fact, artemisinin treatment failures have already been announced in a few
isolated instances. Most of these cases are from regions known to cultivate multi-drug resistant
strains and many question if the failure was truly from growing resistance or from the patient’s
medication non-compliance. In any case, this unusual delay in the parasite development of drug
resistance could arise in part from artemisinin’s very short half-life as discussed above which
could prevent adaptive resistance typically formed in lingering sub-therapeutic drug level
environments. Another cause for delayed artemisinin resistance could be the early decision to
use artemisinin drugs in combination therapies (ACT’s) with longer acting drugs [3]. Numerous
studies show that ACT treatment results in decreased rates of recrudescence and cases of latent
infection. Some examples of artemisinin deriviates and ACT use are shown in Figure 5.
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Figure 5- Artemisinin Derivatives and ACT's [39]
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Malaria Therapeutics Development
The ever increasing rate of drug resistance has awakened a renewed effort in drug
discovery over the past decade. In fact most current treatment options show some degree of
resistance or exhibit the classical signs of the emergence of resistance (Table 1)
Table 1- Existing Antimalarial Drugs and Their Use [40]
Common name
Artemisinins (artemether,
artesunate,
dihydroartemisinin)

Chemical class

Clinical use

Resistance

Sesquiterpene lactone
endoperoxide

In artemisinin-based
combination therapies (ACTs)

Possibly emerging

Lumefantrine

Arylamino alcohol

Most common first-line
antimalarial therapy in Africa,
in combination with artemether

No evidence of
high-level
resistance

Amodiaquine

4-Aminoquinoline

In combination with artesunate
in parts of Africa

Limited crossresistance with
chloroquine

Piperaquine

Bisquinoline

In combination with
dihydroartemisinin in parts of
southeast Asia

Observed in China
following singledrug therapy

Mefloquine

4-Methanolquinoline

In combination with artesunate
in parts of southeast Asia

Prevalent in
southeast Asia

Pyronaridine

Acridine-type
Mannich base

Being registered for combined
use with artesunate

No crossresistance with
other drugs
reported

Quinine/quinidine

4-Methanolquinoline

Mainly for treating severe
malaria, often with antibiotics

Exists at a low
level

Atovaquone

Naphthoquinone

In combination with proguanil
(a biguanide) for treatment or
prevention

Has been observed
clinically

Chloroquine

4-Aminoquinoline

Pyrimethamine

Diaminopyrimidine

Primaquine

8-Aminoquinoline
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Former first-line treatment for
uncomplicated malaria
For intermittent preventive
treatment, combined with
sulphadoxine (a sulphonamide)
For eliminating liver-stage
parasites, including dormant
forms of Plasmodium vivax

Widespread
Widespread

Unknown

The ability to find new antimalarial drugs requires collaborations between pharmaceutical
companies, academia and government agencies for any hope of a speedy resolution. Two such
collaborations, Guiguemde et al. and Gamo et al., submitted their work in 2010 and showed how
partnerships can be used to resupply our antimalarial pipeline [41, 42]. Both studies used highthroughput screening of vast chemical libraries to find new chemical classes that demonstrate
antimalarial activity. Medicines for Malaria Venture (MMV) is a drug discovery hub where
pharmaceuticals, academia and government funding compile data and collaborate to find the cure
for malaria. Unfortunately, even with this collaborative support effort, finding novel antimalarial
candidates is proving to be very difficult. The current antimalarial pipeline is shown in Table 2.
In order for the pipeline to maintain continuous flow, new leads must frequently be identified.
One of the most common methods of lead generation is through screening of synthetic
compound or natural product libraries. Once leads are identified, medicinal chemistry can begin
with lead optimization. The lead will cycle multiple times between screening and optimizing
until the best possible pre-clinical candidate is generated.
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Table 2- MMV Antimalarial Pipeline
(http://www.mmv.org/research-development/rd-portfolio.) [43]

Compounds from synthetic libraries have known chemical synthetic schemes and
possibly some understanding of mechanism of action from previous screening in other systems.
In contrast, natural product libraries are typically extracts containing up to hundreds of
compounds which can be screened for activity against various targets/organisms. If the extract
shows some activity it will be sent for dereplication, a process that isolates the compounds from
17

one another within an extract. In either case, synthetic or natural, once a compound is identified
as the source of activity, cytotoxic analysis is done to rule out any early cytotoxic concerns and
to develop a therapeutic window called the selectivity index. It is also common to run an ADME
(Absorption, Distribution, Metabolism, and Excretion) profile on the early lead compound to
determine any preliminary pharmacodynamics or pharmacokinetic pitfalls. Following this frontend intensive pattern for drug lead discovery will save millions of dollars and significantly speed
up drug approval processing once the drug candidate is found.

Marine Natural Products
With the oceans covering over 70% of the world and 34 of the 36 known phyla of life
contained therein, marine life presents itself as a relatively untapped reservoir for novel
chemotherapeutics. In the 1950's the first bioactive marine chemicals spongothymidine and
spongouridine were purified from the Tethya crypta sponge [44]. Since those initial discoveries,
over 15,000 novel and bioactive marine natural products have been isolated [45] and many have
shown to have excellent anti-inflammatory, antifungal, anti-infective, antimicrobial, anticancer,
antituberculosis, and antiprotozoal activity. A few examples of bioactive marine natural
products and their targets are listed in table 3. Many of these marine natural products (MNPs)
have gone on to clinical trials and many others are still in early development.
In 1992, the sesquiterpenes chemical class was isolated from the Australian sponge
Acanthella klethra and was shown to have antimalarial activity [46]. Over the following 20
years many different chemical classes showing potent antimalarial activity have been identified
from marine life; Including sponges, marine bacteria, and colonial ascidians [47].
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Table 3- Selection of marine compounds with potent and varied activities.[48]
Drug Class
Compound
Organism
Chemistry
IC50
Antibacterial

Ascochytatin

Fungus

Polyketide

0.3µg

Antibacterial

L-Amino acid oxidase
SSAP

Rockfish

Protein

0.078-0.63
µg/mL

Antibacterial
Antibacterial

Arenicin-1
Isoaaptamine

Polychaete
Sponge

Peptide
Alkaloid

Antibacterial

Sesterterpenes

Sponge

Terpenoid

Anticoagulant

Anticoagulant pepetide

Bivalve

Antifungal

Holothurin B

sea cucumber

Antifungal

Neopeltolide

Sponge

Protein
Triterpenoid
glycoside
Polyketide

Antiprotozoal

Plakortide

Sponge

Polyketide

Antiprotozoal
Antiprotozoal
Antituberculosis

Viridamides A & B
Chaetoxanthone B
Bipinnapterolide B
8'-Odemethylisonigerone

Bacterium
Fungus
Coral

Peptide
Polyketide
Terpenoid

Fungus

Polyketide

Antituberculosis

Parguesterols A and B

Sponge

Antiviral

Esculetin ethyl ester
Cryptonemia crenulata
galactan
6,6'-Bieckol
Mirabamides A, C and D

Antituberculosis

Antiviral
Antiviral
Antiviral
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2µg/mL
3.7µg/mL
1.5612.5µg/mL
77.9nM
1.56µg/mL

Sponge

Triterpenoid
glycoside
Polyketide

0.62µg/mL
0.52.3µg/mL
1.1-1.5µM
1.5µg/mL
128 µg/mL
21.5 & 43.0
µM
7.8 &
11.2µg/mL
46 µM

Alga

Polysaccharide

0.8-16µg/mL

Alga
Sponge

Skikimate
Peptide

1.07-1.72 µM
0.041-3.9 µM

CHAPTER TWO: MATERIALS AND METHODS
Culturing P. falciparum
P. falciparum Dd2 and 3D7 strains were cultured using a modified Trager and Jensen
method [49] in RPMI media with L-glutamine (Invitrogen) and supplemented with 25mM
HEPES, 26 mM NaHCO3, 2% dextrose, 15mg/L hypoxanthine, 25mg/L gentamycin, and 0.5%
Albumax I. Culture media was changed daily and incubated at 37°C in 5% CO2 and 95% air.
The 3D7 strain is a chloroquine sensitive strain characterized as chloroquine sensitive,
pyrimethamine sensitive, mefloquine sensitive, and artemisisin sensitive. The Dd2 strain was
used as a chloroquine resistant strain with resistance to chloroquine, pyrimethamine, and
mefloquine but sensitivitity to artemisinin. A blood smear was done daily and a Giemsa stain
was used to determine parasitemia. When parasitemia reached 10-15%, the culture was split
down and resupplied with washed and 50% diluted A+ blood received from the Central Florida
Blood Bank.

SYBR Green-I Fluorescence Assay
In comparing antimalarial screening assays it is clear that SYBR Green I is both less
expensive than PICOGREEN and [H3]-hypoxanthine incorporation assays and also produces the
lowest signal to noise ratio of the three assays in screening of natural product extracts [50] Given
these two advantages, SYBR Green I was selected as our means of determining antimalarial
activity. Because the Plasmodium falciparum host is the RBC which has no DNA, and since
SYBR Green is a known DNA intercalating agent which will emit excitation induced light only

20

after binding to DNA, this assay can be used to quantify DNA levels and therefore, to quantify
inhibition levels.
Different dilutions of the compound/fraction in 1 µl of the culture medium were added to
99 µl of P. falciparum culture at a 1% parasitemia and 2% hematocrit in 96-well plates.
Maximum DMSO concentration in the culture never exceeded 0.125%. Chloroquine at 1 µM
was used as a positive control to determine the baseline value. Following 72 hours incubation at
37ºC, the plates were frozen at -80ºC. After thawing the plates at room temperature 100 µl of
lysis buffer (with 20mM Tris-HCL, 0.08% Saponin, 5mM EDTA, 0.8%Triton X-100, and 0.01%
SYBR Green I) was added to each well. Plates were incubated in the dark for 30 minutes at 37ºC
followed by fluorescence emission reading using a Synergy H4 hybrid multimode plate reader
(Biotek) set at 485nm excitation and 530nm emission.

Fibroblast Cytotoxicity Assay
Compounds were evaluated for cytotoxicity using NIH/3T3 fibroblast cells. A 384 well
plate was seeded with 2,500 cells/well (total volume 50µL) and incubated for 24 hours. Serial
dilutions of the compound were added to the plate and plates were incubated for an additional 48
hours. Fifty µL MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium), CellTiter 96® Aqueous non-radioactive cell proliferation assay,
Promega] reagent was added to each well and the plates were incubated for an additional 3
hours. Cell viability was obtained by measuring the absorbance at 490nm using Synergy H4
hybrid multimode plate reader (Biotek).
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Sensitivity and Reliability Statistical Analysis
In order to validate active hits and recognize and quantify sensitivity and accuracy of
each assay we utilized a Z-factor analysis. This assay was originally developed by Zhang et al
[51], for HTS validation. The equation is shown below. The Z-factor is a range from 0 to 1. The
closer the score is to the value of 1, the more ideal are the assay conditions and the more valid
are the hit results. A value below 0.5 is considered unreliable and perhaps requires some
modifications before the assay can be re-run. A value between 0.5 and 1 is considered
acceptable for hit validation
(
(
(

)
)
)

Where σp represents the standard deviation of the positive controls and σn is the standard
deviation of negative controls. Also, µp represents the mean of the positive controls and µn
represents the mean of the negative controls.
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CHAPTER THREE: IDENTIFICATION OF NOVEL ANTIMALARIALS FROM
MARINE NATURAL PRODUCTS
Primary Screening of HBOI Peak Fractions
The Harbor Branch Oceanographic Institute in Fort Pierce, Florida began marine natural
product drug discovery in 1984. The HBOI collection program has two specific aims: to
maximize taxonomic diversity; and to evaluate how ecological factors relate to secondary
metabolite expression. Dedication to these two primary aims has already resulted in the
publication of over 100 bioactive marine natural products and over 96 patents to protect these
discoveries. Their vast library includes many uncommon marine organisms, primarily collected
by the Johnson Sea-Link submersible, which is capable of collecting samples at depths of almost
1000m, an order of magnitude deeper than typical scuba-access derived collection (<100m).
Given the proximity of HBOI and their unique collection of marine life fractions we
began a collaborative effort to screen over 2,600 marine natural product peak fractions in search
of novel antimalarial chemical scaffolds. This joint UCF-HBOI drug development scheme is
depicted in figure 6 below
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.
Figure 6-UCF-HBOI Drug Development Scheme

In the screening process we quickly identified two-hundred fifty-three active fractions
against the chloroquine sensitive Plasmodium 3D7 strain. Any fraction which demonstrated
greater than 70% inhibition of parasite at a concentration of 5µg/ml was defined as an active
fraction. A list of macroorganims sources for these fractions can be found in table 4.

Table 4 Macroorganism Sources of Active Peak Fractions
Coral
Number of Different
Species with Active
Fractions

3

Active Peak Fraction Origins
(active = >70% inhibition @ 5μ/ml)
Sponge
Mollusk
13

1

Other
3

The active fractions were next prioritized by selecting the top 2 active fractions per
species. This resulted in 31 active fractions which were then screened against the 3d7 parasite
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strain at different concentrations to determine the IC50. Table 5 represents the result of this
screening process. These results were sent back to HBOI where the fractions were further
purified and dereplicated.
Table 5 Antimalarial Activity of HBOI Peak Fractions

Fraction

3D7 IC50
(ug/ml)

Fraction

3D7 IC50
(ug/ml)

Fraction

3D7 IC50
(ug/ml)

12.A09
13.H07
16.A01
18.A01
18.A10
18.C05
18.D08

0.73
1.1
0.67
0.62
0.52
0.23
0.73

18.F01
18.G07
22.A01
23.F01
24.C05
27.B10
27.C10

0.98
0.44
0.82
1.1
0.21
0.51
0.47

30.A01
31.C08
32.C02
33.A03
39.A05
39.A06
39.A10

0.99
1.1
0.08
1.2
0.75
0.6
0.85

18.EO3

0.96

29.A07

0.52

All data are the mean of at least three independent experiments.

Primary Screening of HBOI Purified Fractions
As the prioritized active fractions were purified and dereplicated, they were fractionated
out and sent back to UCF for additional screening. Over 200 purified fractions were received
from HBOI in two separate shipments. The purified fractions from the first shipment were
screened against the chloroquine resistant Dd2 strain and the results are shown in table 6.
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Table 6- Purified fractions antiplasmodial IC50
Fraction

Field ID

Dd2
IC50

Fraction

Field ID

Dd2
IC50

4.B07

Aplysina sp.

1.20

18.D08

Paramuriceidae

0.73

7.G05
7.G11

Peysonellia
Peysonellia

1.30
1.00

18.EO3
18.F01

Paragorgai
Spongosorites

0.96
0.34

9.G07
10.C11

Axinellida?
Spirastrella sp.

0.80
0.90

18.G03
18.G07

Paramuriceidae Unid. sp.
Paramuricea sp.

0.83
0.44

10.D08
10.D09
11.A08

Gastropoda, Aplysia? sp.
Gastropoda, Aplysia? sp.
Gorgonacea

0.10
0.50
1.20

22.A01
23.F01
24.C05

Dendroceratida
Erylus sp.
Pachastrellidae

0.82
1.12
0.46

11.H01

Axinellida

1.20

27.C10

Amphibleptula

0.47

11.H02

Axinellida

1.20

29.A07

Axinellidae

1.24

12.A09
12.A10
13.H07
15.D04
15.D07
15.H06
18.A01
18.A10

Axinellida
Axinellida
Leiodermatium? sp.
Xestospongia? sp.
Xestospongia? sp.
Halichondrida?
Poecillastra
Plexauridae

0.74
0.26
1.13
1.58
1.30
1.25
1.93
1.44

30.A01
30.B11
31.B11
31.C08
32.C02
33.A03
39.A05
39.A06

Spongiidae
Spongiidae
Choristida
Choristida
Halichondriidae
Spongiidae
Aplysina
Aplysina

0.99
1.43
1.40
1.17
1.20
1.20
0.75
0.60

18.C04

Myrmekioderma styx

0.65

39.A10

Aplysina

0.85

All data are the mean of at least three independent experiments.

All fractions with an IC50 at or below 1µg/mL were further screened for cytotoxicity.
Unfortunately, several of these fractions were depleted prior to cytotoxicity screening and were
hence removed from further analysis at this time. The resulting selectivity indices are shown in
table 7 and further dereplication of a few of these fractions was included in the second shipment
from HBOI. The dereplication of the remainder of these active fractions will be occurring in the
near future.

26

Table 7- Selectivity indices of all fractions with <1µg/mL IC50 in Dd2
Fraction

Field ID

Dd2
IC50

NIH 3T3
IC50

Selectivity
Index

7.G11

Peysonellia

1.00

47

47

9.G07

Axinellida?

0.80

33

41

10.C11

Spirastrella sp.

0.90

48

53

10.D08

Gastropoda, aplysia? sp.

0.10

31

310

10.D09
18.D08

Gastropoda, aplysia? sp.
Paramuriceidae

0.50
0.73

29
>50

59
>68

18.EO3

Paragorgai

0.96

>50

>52

18.G07

Paramuricea sp.

0.44

>50

>113

27.C10

Amphibleptula

0.47

>50

>105

39.A05

Aplysina

0.75

>50

>67

39.A06

Aplysina

0.60

>50

>83

39.A10

Aplysina
0.85
>50
>59
All data are the mean of at least three independent experiments.

The second shipment of purified fractions also contained several active purified fractions
from 7 distinct species which all showed to have antiplasmodial activity in the initial screening
tests. Among this shipment were the purified fractions from species which had multiple active
fractions in the initial screening, including: Choristida sp., Bebryce sp., Amphibleptula sp.,
Aplysina sp., and Auletta sp. derive fractions. The top fraction from each organism is listed in
table 8. These results have been sent back to HBOI and further dereplication and purified
compound isolation from all active purified fractions is underway.
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Table 8- Potent antimalarial HBOI purified fractions
Organism ID
Genus
IC50 (µg/mL)
10-V-00-1-004

Bebryce sp.

0.47

31-III-89-2-003

Amphibleptula sp.

0.73

10-V-00-3-009

Aplysina sp.

0.77

11-V-00-3-009

Auletta sp.

0.83

23-XI-96-1-006

Choristida sp.

1.2

All data are the mean of at least three independent experiments.
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CHAPTER FOUR: STRUCTURE ACTIVITY RELATIONSHIP PROFILE FOR
PREVIOUSLY IDENTIFIED HIT- NORTOPSENTIN A
Primary Screening of Nortopsentin A Analogs
Early screening of the first 336 HBOI purified fractions resulted in a potential hit from
the genus Spongosorites spp known as Nortopsentin A. The bis(indoyl)imidazole Nortopsentin
A (Figure 8).

Figure 7 Nortopsentin A Structure

The antimalarial activity of nortopsentin A had never been shown before. Nortopsentin
A was purified and sent to UCF for additional screening. Nortopsentin A demonstrated effective
antimalarial activity in both the 3D7 (choloroquine sensitive) and the Dd2 (chloroquine resistant)
strains.
The mechanism of action for nortopsentin A was previously studied in our laboratory by
culturing parasites in nortopsentin A drug treated culture. In that study nortopsentin A was
shown to inhibit development beyond the early trophozoite stage which supported the claim of
previous studies which showed that topsentin compounds can intercalate with DNA and inhibit
DNA synthesis [52].
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With this potentially novel mechanism of action among antimalarials, nortopsentin A was
escalated in lead development. Recent screening for antiplasmodial and cytotoxicity IC50 show
an IC50 for Nortopsentin A against Dd2 at 580nM and a cytotoxicity IC50 value of 6µM as shown
in Figure 9.

A

B

Figure 8- In-Vitro Antimalarial and Cytotoxic Analysis of Nortopsentin A.
(A) Determination of the antimalarial activity of nortopsentin A in Dd2 strains of P. falciparum.
Asynchronous cultures were exposed to different concentrations of inhibitor for 72 hrs.
(B) Cytotoxicity of nortopsentin A. Varying concentrations of nortopsentin A was incubated
with NIH 3T3 fibroblast cells for 48 hours to determine the cytotoxicity IC50 value. All data
shown are the result of at least 3 independent experiments.
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Structure Activity Relationship Profiling
In order to assist medicinal chemistry in lead optimization, it is important to develop a
structure activity relationship for any potential lead. For the compound nortopsentin A, six
chemical analogs were selected. These six analogs, along with nortopsentin A, were screened
against the chloroquine resistant Plasmodium strain Dd2. Following an IC50 determination, all
compounds were also screened for cytotoxicity against the NIH 3T3 fibroblast cell line using the
MTS cell viability assay described in the methods section. This data was collected and used to
determine a selectivity index for each compound and is shown in Table 8.
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Table 9 Bis(indolyl)imidazole Structural Analogs
Compound
Name

DD2
EC50
(µM)

Structure

Cytotoxicity
Selectivity
NIH 3T3
Index
(µM)

Nortopsentin A

0.58

6

10

Hamacanthin-A

3.2

30

9.4

Dragmacidin-D

5.2

27

5.2

Dragmacidin

6.4

7

1.1

Bis(2,2)-6-Brindol-3yl-Ethylamine

6.5

11

1.7

Deoxytopsentin

8.4

20

2.4

Hamacanthin-B

>20

38

<1.9

All data are the mean of at least three independent experiments.
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CHAPTER FIVE: DISCUSSION
HBOI Marine Peak Fraction Library
Culture screening of over 2,600 marine peak fractions from the Harbor Branch
Oceanographic Institute against the 3d7 strain of Plasmodium falciparum resulted in 253
fractions which inhibit at least 70% of parasite growth at 5µg/mL. This nearly 10% hit rate is
consistent with typical natural product library screening showing significantly higher hit rate
percentages as compared to synthetic library screening, as mentioned previously. From these
253 compounds we identified 20 species of marine organisms which inhibit Plasmodium
falciparum growth from which the 35 fractions were selected for further study. 83% of the 35
fractions were also active in the chloroquine resistant Plasmodium falciparum Dd2 strain.
Further dereplication led to purified fractions from 6 different species, one of which,
Spongosorites sp, is the source of the antimalarial near-early lead compound nortopsentin A as
discussed previously. Five additional compounds from four chemical classes have also been
identified from these species and they are shown along with their genus source in table 10.
Additional structure activity relationship profiling, pharmacodynamics/pharmacokinetic studies
and medicinal chemistry for these five compounds may reveal additional novel antimalarial early
drug leads.
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Table 10-UCF-HBOI novel antimalarial compounds
Compound Structure
Source of compound (Genus)

Aplysina sp.

Bebryce sp.

Bebryce sp.

Amphibleptula sp.

Choristida sp.
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Nortopsentin A Structure Activity Relationship
The preliminary screening of nortopsentin A showed antimalarial activity in both
chloroquine sensitive and chloroquine resistant strains. A novel mechanism of action among
antimalarial drugs was also demonstrated. To further escalate nortopsentin A towards lead
development, a collection of six structural analogs, along with nortopsentin A, was sent from the
HBOI library for development of a structure activity relationship.
Of all the compounds tested, nortopsentin A was the most potent and had the greatest
selectivity. Addition of a keto group both decreased antiplasmodial activity and selectivity as
seen in deoxytopsentin. With respect to all the nitrogenated six member heterocycle rings tested,
low µM antiplasmodial activity was maintained and selectivity decreased steadily with respect to
the level of saturation which could be due to subsequent molecular loss of planarity. The only
exception to this trend was hamacanthin A. Interestingly, when the pyrazinone linker attachment
in hamacanthin A changes to the 5 position the antiplasmodial activity is lost, as seen with
hamacanthin B. It seems from this structure activity relationship profile that molecular planarity
and a maintained distance between the two indole rings is essential for optimal antimalarial
activity.
Although nortopsentin A had the best activity and selectivity, further medicinal chemistry
is needed to widen the selectivity index before the compound can be escalated to early drug lead
status.
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Future Directions
There is a critical need to find new antimalarial chemical scaffolds. This screening of
2,835 marine peak fractions has identified 5 new chemical classes which inhibit Plasmodium
falciparum at submicromolar levels.

One of these classes, the topsentin class from the

Sporosorites sp., appears to intercalate parasite DNA and prevent DNA synthesis. This is a
novel mechanism of action amongst current antimalarial drugs. From the structure activity
relationship profile it is clear that the antimalarial potency of topsentin compounds is dependent
upon the distance between the two indole rings and the molecular planarity of the compound.
Future studies will include medicinal chemistry optimization of nortopsentin A to enlarge
the selectivity index before the compound can be escalated in pre-clinical drug development.
The mechanism of action and structure activity relationships for each of the four additionally
identified scaffolds is also necessary. Furthermore, it is anticipated that dereplication of the
purified peak fractions from the nine newly identified species with submicrogram/mL IC50, will
likewise reveal additional novel antimalarial scaffolds which can then be escalated along the
established UCF-HBOI drug development scheme.
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